DRKS00011321已完成2 期
An open, single center, single-arm phase II study to evaluate the safety of a modificated perioperative analgesia with Indometacin during pancreaticoduodenectomy - InPaFis
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 58
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •1. Age >=18 years
- •2. Indication for pancreatoduodenectomy
- •3. Signed informed consent
排除标准
- •1. Perioperative application of platelet aggregation inhibitors
- •2. Application of other NSARs
- •3. Application of selective serotonin reuptake inhibitors, Triamteren oder Diflunisal
- •4. Preexisting ischemic heart disease
- •5. Preexisting peripheral arterial disease
- •6. Preexisting cerebrovascular disease
- •7. Morbus Crohn
- •8. Colitis ulcerosa
- •9. Pregnancy and breast-feeding
- •10. Persons of child-bearing potential not willing or able to use safe methods of contraception
- •11. Preexisting allergies on other substances, pollen or allergic asthma
- •12. Limited legal competence
- •13. Participation in another intervential trial that could interfere with the treatment or outcome of this study
研究者
相似试验
尚未招募
2 期
A phase II, open, single arm, single center study to evaluate the efficacy and safety of compound Huangdai tablets for advanced liver cancerprimary liver cancerITMCTR2100005192Changhai Hospital, Navy Military Medical University, Shanghai
进行中（未招募）
不适用
Study to evaluate the efficacy and safety of the trial substance BIBW 2992 (Afatinib) for treatment of patients with prostate cancer after failure of treatment with docetaxel or ineligible for treatment with docetaxelPatients with HER2-positive, hormone-refractory prostate cancer after failure of treatment with docetaxel or ineligible for treatment with docetaxel.MedDRA version: 13.1Level: LLTClassification code 10062904Term: Hormone-refractory prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-024164-18-DEniversity Medical Center Hamburg-Eppendorf
进行中（未招募）
2 期
Single-arm, open-label, multicentre phase II study evaluating the efficacy and safety of BIBW 2992 (Afatinib) in combination with vinorelbine for the treatment of patients with metastatic breast cancer with intermediate HER2 expression (HER2 2+ by immunohistochemistry, fluorescence in-situ hybridisation (FISH) negative) after failure of first-line therapy in the metastatic setting and having been pre-treated with anthracyclinesMedDRA - 10027475 (LLT): Metastatic breast cancerC50.9Breast, unspecifiedDRKS00003549niversitätsklinikum Magdeburg2
进行中（未招募）
1 期
BIBW 2992 (Afatinib) in combination with vinorelbine for the treatment of patients with metastatic breast cancer with intermediate HER2 expressioMetastatic breast cancer patients with intermediate HER2 expression (IHC 2+, HER2 FISH-negative)MedDRA version: 14.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001765-41-DEMedizinische Fakultät der Otto-von-Guericke Universität Magdeburg Universitätsklinikum Magdeburg A.ö.R.
进行中（未招募）
1 期
A Phase II, open-label, single arm study to evaluate the safety, efficacy, and pharmacokinetics of twice daily midostaurin (PKC412) combined with standard chemotherapy and as a single agent post-consolidation therapy in children with untreated FLT3-mutated AMuntreated FLT3-mutated acute myeloid leukemiaMedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2017-004830-28-DEovartis Pharma AG23